Tysabri 150 mg/ml Injektionslösung in einer Fertigspritze Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

tysabri 150 mg/ml injektionslösung in einer fertigspritze

biogen switzerland ag - natalizumabum - injektionslösung in einer fertigspritze - natalizumabum 150 mg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.45 mg. - multiple sklerose - biotechnologika

Xolair 75 mg Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

xolair 75 mg pulver und lösungsmittel zur herstellung einer injektionslösung

novartis pharma schweiz ag - omalizumabum - pulver und lösungsmittel zur herstellung einer injektionslösung - praeparatio cryodesiccata: omalizumabum 75 mg, histidini hydrochloridum monohydricum, histidinum, saccharum, polysorbatum 20, pro vitro. solvens: aqua ad iniectabile 2 ml. - allergisches asthma, chronische spontane urtikaria, nasenpolypen - biotechnologika

Xolair 150 mg Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

xolair 150 mg pulver und lösungsmittel zur herstellung einer injektionslösung

novartis pharma schweiz ag - omalizumabum - pulver und lösungsmittel zur herstellung einer injektionslösung - praeparatio cryodesiccata: omalizumabum 150 mg, histidini hydrochloridum monohydricum, histidinum, saccharum, polysorbatum 20, pro vitro. solvens: aqua ad iniectabile. - allergisches asthma, chronische spontane urtikaria, nasenpolypen - biotechnologika

Epysqli Europäische Union - Deutsch - EMA (European Medicines Agency)

epysqli

samsung bioepis nl b.v. - eculizumab - hämoglobinurie, paroxysmal - immunsuppressiva - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

Ultomiris Europäische Union - Deutsch - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hämoglobinurie, paroxysmal - selektive immunsuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Dimethyl fumarate Neuraxpharm Europäische Union - Deutsch - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimethylfumarat - multiple sklerose, schubförmig-remittierender - immunsuppressiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Idefirix Europäische Union - Deutsch - EMA (European Medicines Agency)

idefirix

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunsuppressiva - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Amgevita 40 mg/0.8 ml Injektionslösung in einer Fertigspritze Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

amgevita 40 mg/0.8 ml injektionslösung in einer fertigspritze

amgen switzerland ag - adalimumabum - injektionslösung in einer fertigspritze - adalimumabum 40 mg, saccharum, polysorbatum 80, acidum aceticum glaciale, natrii hydroxidum corresp. natrium 0.26 mg, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew), morbus crohn bei erwachsenen sowie kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, hidradenitis suppurativa, uveitis - biotechnologika

Amgevita 40 mg/0.8 ml Injektionslösung im Fertigpen Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

amgevita 40 mg/0.8 ml injektionslösung im fertigpen

amgen switzerland ag - adalimumabum - injektionslösung im fertigpen - adalimumabum 40 mg, saccharum, polysorbatum 80, acidum aceticum glaciale, natrii hydroxidum corresp. natrium max. 0.26 mg, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew), morbus crohn bei erwachsenen, colitis ulcerosa, psoriasis bei erwachsenen - biotechnologika

Hyrimoz 40 mg/0.8 ml Injektionslösung in Fertigspritzen Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

hyrimoz 40 mg/0.8 ml injektionslösung in fertigspritzen

sandoz pharmaceuticals ag - adalimumabum - injektionslösung in fertigspritzen - adalimumabum 40 mg, acidum adipicum, acidum citricum monohydricum, natrii chloridum, mannitolum, polysorbatum 80, natrii hydroxidum aut acidum hydrochloridum, aqua ad iniectabile ad solutionem pro 0.8 ml corresp. natrium 2.34 mg. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew), morbus crohn bei erwachsenen sowie kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen und jugendlichen ab 47 kg körpergewicht, hidradenitis suppurativa (acne inversa), uveitis - biotechnologika